Skip to main content

Advertisement

SpringerLink
Log in

Calcium Antagonists in the Elderly

A Risk-Benefit Analysis

  • Review Article
  • Adverse Effects
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Calcium antagonists are effective in lowering blood pressure, relieving anginal symptoms and improving exercise tolerance in older and younger patients with coronary artery disease. Verapamil and diltiazem are effective in slowing ventricular response rates to supraventricular arrhythmias in both older and younger patients. Although they belong to at least 3 distinct chemical classes, a moderate decrease in the clearance of ail calcium antagonists occurs with aging. Most clinical trials of these drugs have used the same dosages in older and younger patients, confounding analyses of sensitivity in older compared with younger patients. Greater reductions in blood pressure usually occur in older compared with younger patients receiving the same dosages of calcium antagonists; similarly, the dosage required to reduce blood pressure to a certain level is usually lower in older compared with younger patients.

Drug acquisition costs are generally higher for calcium antagonists than for β-blockers or diuretics. Compared with younger patients, greater heart rate suppression may be seen in older patients treated with verapamil and diltiazem; conversely, heart rate increases are usually seen with dihydropyridines. Calcium antagonists have not been shown to provide long-term benefits or decreased morbidity or mortality in elderly patients with hypertension. Verapamil, but not dihydropyridines, decreases mortality after myocardial infarction in patients without congestive heart failure. Calcium antagonists have not been shown to be beneficiai in the treatment of acute stroke.

Adverse effects, such as postural hypotension, may be more frequent in elderly compared with younger patients. In addition, the elderly are at greater risk for drug interactions with calcium antagonists due to the higher likelihood that they are receiving other drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Administration US FDA. Drug utilization in the U.S., 1989. 11th annual review. PB 1991; 91 (198838)

  2. Schwartz JB. Clinical pharmacology. In: Hazzard WR, Bierman EL, Blass JP, et al., editors. Principies of geriatric medicine and gerontology. 3rd ed. McGraw-Hill, Inc.: 259–76

  3. Abernethy D, Schwartz J, Todd E, et al. Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Ann Intern Med 1986; 105: 329–36

    PubMed  CAS  Google Scholar 

  4. Abernethy D, Wainer I, Longstreth J, et al. Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. J Pharmacol Exp Ther 1993; 266: 904–11

    PubMed  CAS  Google Scholar 

  5. Ahmed J, Meredith P, Elliott H. The influence of age on the pharmacokinetics of verapamil. Pharmacol Res 1991; 24: 227–33

    Article  PubMed  CAS  Google Scholar 

  6. Schwartz J. Aging alters verapamil elimination and dynamics: single dose and steady-state responses. J Pharmacol Exp Ther 1990; 255: 364–73

    PubMed  CAS  Google Scholar 

  7. Schwartz J, Troconiz I, Verotta D, et al. Aging effects on stereoselective pharmaeokinetics and pharmacodynamics of verapamil. J Pharmacol Exp Ther 1993; 265: 690–8

    PubMed  CAS  Google Scholar 

  8. Schwartz J, Capili H, Daugherty J. Aging of women alters Sverapamil pharmaeokinetics and pharmacodynamics. Clin Pharmacol Ther 1994; 55: 509–17

    Article  PubMed  CAS  Google Scholar 

  9. Robertson D, Waller D, Renwick A, et al. Age-related changes in the pharmaeokinetics and pharmacodynamics of nifedipine. Br J Clin Pharmacol 1988; 25: 297–305

    Article  PubMed  CAS  Google Scholar 

  10. Abernethy D, Gutkowska J, Winterbottom L. Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. Clin Pharmacol Ther 1990; 48: 76–86

    Article  PubMed  CAS  Google Scholar 

  11. Abernethy D, Gutkowska J, Lambert M. Amlodipine in elderly hypertensive patients: pharmaeokinetics and pharmacodynamics. J Cardiovasc Pharmacol 1988; 12 (Suppl.): S67–S71

    Article  PubMed  Google Scholar 

  12. Laplanche R, Feril B, Nuesch E, et al. Exploratory analysis of population pharmacokinetic data from clinical trials with application to isradipine. Clin Pharmacol Ther 1991; 50: 39–54

    Article  PubMed  CAS  Google Scholar 

  13. Wade J, Sambol N. Felodipine population dose-response and concentration-response relationships in patients with essential hypertension. Clin Pharmacol Ther 1995; 57(5): 569–81

    Article  PubMed  CAS  Google Scholar 

  14. Lettieri J, Krol G, Yeh S, et al. The effects of age and race on nitrendipine pharmaeokinetics and pharmacodynamics. J Cardiovasc Pharmacol 1988; 12(4): S129–S132

    Article  PubMed  CAS  Google Scholar 

  15. Blychert E, Edgar B, Elmfeldt D, et al. A population study of the pharmaeokinetics of felodipine. Br J Clin Pharmacol 1991; 31: 15–24

    Article  PubMed  CAS  Google Scholar 

  16. Baksi A, Edwards J, Ahr G. A comparison of the pharmaeokinetics of nisoldipine in elderly and young subjects. Br J Clin Pharmacol 1991; 31: 367–70

    Article  PubMed  CAS  Google Scholar 

  17. Forette F, Bellet M, Henry J, et al. Effect of nicardipine in elderly hypertensive patients. Br J Clin Pharmacol 1985; 20Suppl. 1: 125S–129S

    Article  PubMed  Google Scholar 

  18. Van Harten J, Burggraaf J, Ligthart G, et al. Single- and multiple-dose nisoldipine kinetics and effects in the young, the middle-aged, and the elderly. Clin Pharmacol Ther 1989; 45:600–7

    Article  PubMed  Google Scholar 

  19. Forette F, McClaren J, Hervy M, et al. Nicardipine in elderly patients with hypertension: a review of experience in France. Am HeartJ 1989; 117:256–61

    Article  CAS  Google Scholar 

  20. Montamat S, Abernethy D. Calcium antagonists in geriatric patients: diltiazem in elderly persons with hypertension. Clin Pharmacol Ther 1989; 45: 682–91

    Article  PubMed  CAS  Google Scholar 

  21. Schwartz J, Abernethy D. Responses to intravenous and oral diltiazem in elderly and younger patients with systemic hypertension. Am J Cardiol 1987; 59: 1111–7

    Article  PubMed  CAS  Google Scholar 

  22. Watkins P, Turgeon D, Saenger P, et al. Comparison of urinary 6-b-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 1992; 52: 265–73

    Article  PubMed  CAS  Google Scholar 

  23. Ryan D, Levin W. Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacol Ther 1990; 45: 153–239

    Article  PubMed  CAS  Google Scholar 

  24. Kroemer H, Gautier J, Beaune P, et al. Identification of P450 enzymes involved in metabolism of verapamil in humans. Arch Pharmacol 1993; 348: 332–7

    Article  CAS  Google Scholar 

  25. Hunt C, Westerkam W, Stave G. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992; 44: 275–83

    Article  PubMed  CAS  Google Scholar 

  26. Hunt C, Westerkam W, Stave G, et al. Hepatic cytochrome P4503A (CYP3A) activity in the elderly. Mech Ageing Dev 1992; 64: 189–99

    Article  PubMed  CAS  Google Scholar 

  27. Geokas MC, Haverback BJ. The aging gastrointestinal tract. Am J Surg 1969; 117:881–92

    Article  PubMed  CAS  Google Scholar 

  28. Ahmed J, Elliott H, Meredith P, et al. Low-dose verapamil in middle-aged and elderly patients with angina pectoris: no evidence of increased susceptibility to the cardiac effects. Cardiovasc Drugs Ther 1992; 6: 153–8

    Article  PubMed  CAS  Google Scholar 

  29. Elkik F, Claudel S, Carcone B, et al. Demographic factors and the antihypertensive effect of diltiazem. J Cardiovasc Pharmacol 1991; 17(5): 685–91

    Article  PubMed  CAS  Google Scholar 

  30. Porchet H, Loew F, Gauthey L, et al. Serum concentration-effect relationship of (±)-nicardipine and nifedipine in elderly hypertensive patients. Eur J Clin Pharmacol 1992; 43: 551–3

    Article  PubMed  CAS  Google Scholar 

  31. Abernethy D. An overview of the pharmaeokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension. Am J Cardiol 1994; 73: 10A–17A

    Article  PubMed  CAS  Google Scholar 

  32. Bravo EL, Krakoff LR, Tuck ML, et al. Antihypertensive effectiveness of nifedipine gastrointestinal therapeutic System in the elderly: the Modern Approach to the Treatment of Hypertension (MATH) Study Group. Am J Hypertens 1990 Dec; 3 (12 Pt 2): 326S–32S

    PubMed  CAS  Google Scholar 

  33. Scott M, Castleden C, Adam H, et al. The effect of ageing on the disposition of nifedipine and atenolol. Br J Clin Pharmacol 1988; 25: 289–96

    Article  PubMed  CAS  Google Scholar 

  34. Lakatta E. Cardiovascular regulatory mechanisms in advanced age. Physiol Rev 1993; 73(2): 413–67

    PubMed  CAS  Google Scholar 

  35. Somberg J, Achari R, Laddu A. Terazosin: pharmaeokinetics and the effect of age and dose on the incidence of adverse events. Am Heart J 1991; 122(3): 901–5

    Article  PubMed  CAS  Google Scholar 

  36. Aronow W, Ahn C. Postprandial hypotension in 499 elderly persons in a long-term health care facility. J Am Geriatr Soc 1994; 42: 930–2

    PubMed  CAS  Google Scholar 

  37. Schneider J, Mion L, Frengley J. Adverse drug reactions in an elderly outpatient population. Am J Hosp Pharm 1992; 49: 90–6

    PubMed  CAS  Google Scholar 

  38. Walker J, Wynne H. Review: the frequency and severity of adverse drug reactions in elderly people. Age Ageing 1994; 23: 255–9

    Article  PubMed  CAS  Google Scholar 

  39. Cumming R, Miller J, Kelsey J, et al. Medications and multiple falls in elderly people: the St Louis OASIS study. Age Ageing 1991; 20(6): 455–61

    Article  PubMed  CAS  Google Scholar 

  40. Schwartz J, Caputo G, Abbot J. Early experience with dobutamine stress testing and cardiac cinetomographic imaging in the elderly: antianginal effects of nifedipine-GITS. J Am Geriatr Soc 1993; 41: 967–74

    PubMed  CAS  Google Scholar 

  41. Physicians desk reference, 49th ed. Montvale, N.J.: Medical Economics Data, 1995

  42. Schwartz J, Nielsen A, Griffin J. Concentration-dependent enhancement of junctional pacemaker activity by verapamil in man. Circulation 1985; 71: 450–7

    Article  PubMed  CAS  Google Scholar 

  43. Schwartz J, Keefe D, Kirsten E, et al. Acute and chronic pharmacodynamic interaction of verapamil and digoxin and atrial fibrillation. Circulation 1982; 65: 1163–70

    Article  PubMed  CAS  Google Scholar 

  44. Gurwitz JH, Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann Intern Med 1991; 114: 956–66

    PubMed  CAS  Google Scholar 

  45. Carbonin P, Pahor M, Bernabei R, et al. Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Soc 1991; 39: 1093–9

    PubMed  CAS  Google Scholar 

  46. Brody JA, Brock DB, Williams TF. Trends in the health of the elderly population. Annu Rev Public Health 1987; 8: 211–34

    Article  PubMed  CAS  Google Scholar 

  47. Schwartz JB, Keefe DL, Kirsten EB, et al. Acute and chronic pharmacodynamic interaction of verapamil and digoxin in atrial fibrillation. Circulation 1982; 65: 1163–70

    Article  PubMed  CAS  Google Scholar 

  48. Belz G, Doering W, Munkes R, et al. Effects of various calcium antagonists on blood level and renal clearance of digoxin. Circulation 1980; 64: 24

    Google Scholar 

  49. Belz G, Doering W, Munkes R, et al. Interaction between digoxin and calcium antagonists and antiarrhythmic drugs. Clin Pharmacol Ther 1983; 33: 410–7

    Article  PubMed  CAS  Google Scholar 

  50. Schwartz J, Migliore P. Effect of nifedipine on serum digoxin concentration and renal digoxin clearance. Clin Pharmacol Ther 1984; 36(1): 19–24

    Article  PubMed  CAS  Google Scholar 

  51. Schwartz J, Raizner A, Akers S. The effect of nifedipine on serum digoxin concentrations in patients. Am Heart J 1984; 107: 669–73

    Article  PubMed  CAS  Google Scholar 

  52. Maisel A, Motulsky H, Insel P. Hypotension after quinidine plus verapamil: possible additive competition at alpha-adrenergic receptors. N Engl J Med 1985; 312(3): 167–70

    Article  PubMed  CAS  Google Scholar 

  53. Price WA, Shalley JE. Lithium-verapamil toxicity in the elderly [letter]. J Am Geriatr Soc 1987; 35: 177–9

    PubMed  CAS  Google Scholar 

  54. Somogyi A, Gugler R. Drug interactions with cimetidine. Clin Pharmacokinet 1982; 7: 23–41

    Article  PubMed  CAS  Google Scholar 

  55. Schwartz J, Upton R, Lin E, et al. Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1988; 43: 673–80

    Article  PubMed  CAS  Google Scholar 

  56. Abernethy D, Schwartz J, Todd E. Lack of interaction between verapamil and cimetidine. Clin Pharmacol Ther 1985; 38:342–9

    Article  PubMed  CAS  Google Scholar 

  57. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991 Jun 26; 265: 3255–64

    Article  Google Scholar 

  58. Hulley S, Furberg C, Gurland B, et al. Systolic hypertension in the elderly program (SHEP): antihypertensive efficacy of chlorthalidone. Am J Cardiol 1985; 56: 913–20

    Article  PubMed  CAS  Google Scholar 

  59. Hall W. Systolic hypertension in the elderly program: implications for the management of older hypertensive patients. Am J Geriatr Cardiol 1992; Jul/Aug: 15–27

    Google Scholar 

  60. Bird A, Blizard R, Mann A. Treating hypertension in the older person: an evaluation of the association of blood pressure level and its reduction with cognitive performance. J Hypertens 1990; 8: 147–52

    Article  PubMed  CAS  Google Scholar 

  61. Fletcher A, Amery A, Birkenhager W, et al. Risks and benefits in the trial of the European working party on high blood pressure in the elderly. J Hypertens 1991; 9: 225–30

    Article  PubMed  CAS  Google Scholar 

  62. Coope J, Warrender T. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 293: 1145–52

    Article  PubMed  CAS  Google Scholar 

  63. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension Detection and follow up program: I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979 Dec 7; 242: 2562–71

    Article  Google Scholar 

  64. Prisant L, Carr A. Overview of the findings of the European party on high blood pressure in the elderly. Geriatr Med Today 1990; 9: 35–8

    Google Scholar 

  65. Wikstrand J, Warnold I, Olsson G, et al. Primary prevention with metoprolol in patients with hypertension: mortality results from the MAPHY study. JAMA 1988; 259: 1976–82

    Article  PubMed  CAS  Google Scholar 

  66. Johannesson M, Jonsson B. A review of cost-effectiveness analyses of hypertension treatment. Pharmaco Economics 1992; 1:250–64

    Article  CAS  Google Scholar 

  67. Drugs for hypertension. Med Lett Drugs Ther 1995; 37(949): 45–50

    Google Scholar 

  68. Hilleman D, Mohiuddin S, Lucas J, et al. Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension. Clin Ther 1994; 16(1): 88–102

    PubMed  CAS  Google Scholar 

  69. Edelson J, Weinstein M, Tostenson A. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990; 263: 408–13

    Article  Google Scholar 

  70. Psaty B, Koepsell T, Yanez N, et al. Temporal patterns of antihypertensive medication use among older adults, 1989 through 1992. JAMA 1995; 273(18): 1436–8

    Article  PubMed  CAS  Google Scholar 

  71. McVeigh G, Flack J, Grimm R. Goals of antihypertensive therapy. Drugs 1995; 49(2): 161–75

    Article  PubMed  CAS  Google Scholar 

  72. McClellan K. Unexpected results from MIDAS in atherosclerosis. Inpharma 1994; 932: 4

    Article  Google Scholar 

  73. Furberg C. Final results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). International Society of Hypertension Meeting: 1994; Melbourne

  74. Gong L, Zwang W, Zhu Y. Shanghai trial of nifedipine in the elderly [abstract]. Seventh European meeting on hypertension: 1995 Jun 12: Milan

  75. Psaty B, Heckbert S, Koepsell T, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274(8): 620–5

    Article  PubMed  CAS  Google Scholar 

  76. Furberg C, Psaty B, Meyer J. Nifedipine dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92(5): 1326–31

    Article  PubMed  CAS  Google Scholar 

  77. Pahor M, Guralnik J, Corti M, et al. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43: 1191–7

    PubMed  CAS  Google Scholar 

  78. Opie L, Messerli F. Nifedipine and mortality: grave defects in the dossier. Circulation 1995; 92: 1068–73

    Article  PubMed  CAS  Google Scholar 

  79. Parmley W, Nesto R, Singh B, et al. Attenuation of the circadian patterns of myocardial ischemia with nifedipine GITS in patients with chronic stable angina. J Am Coll Cardiol 1992; 19(7): 1380–9

    Article  PubMed  CAS  Google Scholar 

  80. Vaage-Nilsen M, Rasmussen V, Hansen J, et al. Effect of verapamil on arrhythmias and heart rate during 16 months following an acute myocardial infarction. Cardiovasc Drugs Ther 1994; 8(1): 147–51

    Article  PubMed  CAS  Google Scholar 

  81. Vaage-Nilsen M, Hansen J, Mellemgaard K, et al. Effect of verapamil on the prognosis of patients with early postinfarction electrical or mechanical complications. Int J Cardiol 1995; 48(3): 255–8

    Article  PubMed  CAS  Google Scholar 

  82. Gheorgiade M, Weiner D, Chakko S, et al. Monotherapy of stable angina with nicardipine hydrochloride: double-blind, placebo-controlled, randomized study. Eur Heart J 1989; 10: 695–701

    Google Scholar 

  83. Scheidt S, Le Winter M, Hermanovich J, et al. Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial. Am J Cardiol 1986; 58: 715–21

    Article  PubMed  CAS  Google Scholar 

  84. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-H). Am J Cardiol 1991; 67: 1295–7

    Article  PubMed  CAS  Google Scholar 

  85. Hansen J. Review of postinfarct treatment with verapamil: combined experience of early and late intervention studies with verapamil in patients with acute myocardial infarction. Cardiovasc Drugs Ther 1994; 8Suppl. (3): 543–7

    Article  PubMed  Google Scholar 

  86. Jespersen C. The effect of verapamil on major events in patients with impaired cardiac function recovering from acute myocardial infarction. Eur Heart J 1993; 14(4): 540–5

    Article  PubMed  CAS  Google Scholar 

  87. Jespersen C. Role of ischemia in postinfarction heart failure: hypothetical considerations based on use of verapamil in the DAVIT II Study. Danish Study Group on Verapamil in Myocardial Infarction. Cardiovasc Drugs Ther 1994; 8(6): 823–8

    Article  PubMed  CAS  Google Scholar 

  88. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385–92

    Article  Google Scholar 

  89. Held P, Yusuf S. Impact of calcium Channel blockers on mortality in survivors of acute myocardial infarction. In: Singh B, Wellens H, Hiraoka M, editors. Electropharmacological control of cardiac arrhythmias. Mount Kisco, NY: Futura Publishing, Co. Inc., 1994:399–411

    Google Scholar 

  90. Fisher M, Grotta J. New uses for calcium Channel blockers: therapeutic implications. Drugs 1993; 46(6): 961–75

    Article  PubMed  CAS  Google Scholar 

  91. Luft F, Haller H. Calcium Channel blockers in current medical practice: an update for 1993. Clin Exp Hypertens 1993; 15(6): 1263–76

    Article  PubMed  CAS  Google Scholar 

  92. Kaste M, Fogelholm R, Erila T, et al. A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemie hemispheric stroke. Stroke 1994; 25(7): 1348–53

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisions of Geriatric Medicine and Clinical Pharmacology, Northwestern University Medical School, Chicago, Illinois, USA

    Janice B. Schwartz

Authors
  1. Janice B. Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Janice B. Schwartz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schwartz, J.B. Calcium Antagonists in the Elderly. Drugs & Aging 9, 24–36 (1996). https://doi.org/10.2165/00002512-199609010-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199609010-00003

Keywords

Search

Navigation